search
Back to results

RTMS Targets Neural Circuits for Smoking Cessation

Primary Purpose

Tobacco Use, Cigarette Smoking

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Sham rTMS
Active rTMS 10 Hz DLPFC
Active rTMS 1 Hz mOFC
Sponsored by
Medical University of South Carolina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Be between the ages of 18 and 60 years old.
  2. Smoke 10 or more cigarettes per day and have a carbon monoxide (CO) level > 10 ppm indicative of recent smoking.
  3. Have not received substance abuse treatment within the previous 30 days.
  4. Meet the criteria for tobacco use disorder as determined by DSM-5.
  5. Be in stable mental and physical health.
  6. If female, test non-pregnant and use adequate birth control.
  7. Show no evidence of focal or diffuse brain lesions on MRI.
  8. Be willing to provide informed consent.
  9. Be able to comply with protocol requirements and likely to complete all study procedures.
  10. Be motivated to quit smoking (based on responses of "very likely," or "somewhat likely" in the motivation questionnaire).

Exclusion Criteria:

  1. Current moderate to severe substance use of any psychoactive substances other than nicotine or caffeine, as defined by DSM-V criteria.
  2. Contraindications to MRI (e.g., presence of metal in the skull, orbital or intracranial cavity, or having claustrophobia).
  3. Contraindication to rTMS.
  4. History of autoimmune, endocrine, viral, or vascular disorders affecting the brain.
  5. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.
  6. Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea.
  7. Lifetime history of major Axis I disorders such as: bipolar affective disorder (BPAD), schizophrenia, post-traumatic stress disorder (PTSD), dementia, suicidal ideation or major depression.
  8. Self-report of >21 standard alcohol drinks per week in any week in the 30 days prior to screening.
  9. Use of other forms of nicotine delivery, such as nicotine patches, electronic cigarettes, gum, nasal spray, inhalers, and nicotine lozenges.
  10. Use of other tobacco products, including cigars, cigarillos, chew, snuff, and pouches/snus.
  11. Previous treatment with TMS.

Sites / Locations

  • Medical University of South CarolinaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Sham Comparator

Active Comparator

Active Comparator

Arm Label

Sham rTMS

Active rTMS 10 Hz DLPFC

Active rTMS 1 Hz mOFC

Arm Description

Participants will be fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device with adjustable output amplitude and powered by a 9-V battery. We will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses or 1 Hz over mOFC total 900 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.

A stimulation frequency of 10 Hz, pulse train duration (on time) of 5 seconds, inter-train interval (off time) of 10 seconds (15 second cycle time), E-field-modeling to determine TMS intensity and coil orientation, total of 60 trains, session time of 15 minutes, and 3000-total pulses per day, will be delivered over the left DLPFC.

A stimulation frequency of 1Hz, E-field-modeling to determine TMS intensity and coil orientation, session time of 15 minutes, and 900-total pulses per day, will be the same for all subjects (both active and sham). TMS will be delivered over the left mOFC.

Outcomes

Primary Outcome Measures

Mean number of cigarettes smoked per day
The primary objective is to compare 1 Hz-mOFC rTMS to 10 Hz-DLPFC rTMS. Cigarettes smoked per day will be the primary outcome measure.
Changes of brain connectivity
Compared to sham rTMS, either active rTMS significantly increase the negative correlation between DLPFC and NAc, DLPFC and mOFC, while decrease the correlation coefficient between NAc and mOFC.

Secondary Outcome Measures

The percentage of participants who have quit by their target quit date
Quit smoke rate on the target quit the date will be measured during the phase.

Full Information

First Posted
May 21, 2021
Last Updated
April 21, 2023
Sponsor
Medical University of South Carolina
Collaborators
National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT04903028
Brief Title
RTMS Targets Neural Circuits for Smoking Cessation
Official Title
RTMS Manipulates Imbalanced Drive-reward and Executive Control Circuitry for Smoking Cessation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 15, 2021 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of South Carolina
Collaborators
National Institutes of Health (NIH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
Cigarette smoking is a significant public health concern. Transcranial magnetic stimulation (TMS) is a non-invasive form of brain stimulation that has already displayed remarkable potential for producing novel, non-pharmacological interventions for depression and cigarette smokers. In this study, we will use brain MRI to guide TMS therapy for smoking cessation.
Detailed Description
Smoking cessation is difficult, despite the demonstrated efficacy of several pharmacotherapeutic agents and cognitive behavioral therapies. This may be due to imbalanced neuronal circuits, including elevated functional connectivity in the drive-reward circuit (medial orbital frontal cortex [mOFC] to nucleus accumbens [NAc]) and decreased functional connectivity in the executive control circuit (dorsolateral prefrontal cortex[ DLPFC] to NAc). Repetitive transcranial magnetic stimulation (rTMS) is a new class of therapeutics that has already displayed remarkable potential for producing novel, non-pharmacological interventions for neuropsychiatric disorders. Previous studies have reported that rTMS decreased cue craving, reduced cigarette consumption, and increased smoking quit rate in tobacco use disorders(TUDs). However, the treatment parameters and exact mechanism for rTMS increasing smoking quit rate need further refinement. The goal of this study is to develop a circuit-based precision rTMS therapy for smoking cessation further. In the 2-year UG3 phase, investigators will recruit 45 TUDs. Participants will undergo a baseline cue-exposure fMRI and a resisting-to smoke fMRI session. Participants will be randomized into three groups: 1) Sham rTMS over the left mOFC or the left DLPFC. 2) Active, inhibitory low-frequency rTMS (LF-rTMS) over the left mOFC (1 Hz, 900 pulses, E-field modeling, 15 minutes, smoking cue exposure fMRI-guided target). Or 3) Active, high-frequency rTMS (HF-rTMS) over the left DLPFC (10 Hz, 3000 pulses, E-field modeling,15 minutes, resisting-to-smoke fMRI guided target). Fifteen sessions of rTMS will be completed over three weeks, after which the investigators will acquire fMRI scans. The investigators will also test the imbalanced function of drive-reward and executive control before and after 3 weeks of treatments to compare the imbalanced function between groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use, Cigarette Smoking

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Forty-five treatment-seeking TUDs between the ages of 18 and 60 will be randomly divided into three groups on a 1:1:1 basis (15 participants/condition). The first condition will receive E-sham rTMS (half will get 1Hz sham; half will get 10Hz sham), the second condition will receive active 1Hz personalized-fMRI and E-field-modeling guided rTMS (900 pulses/session) over the left mOFC, and the third condition will receive active 10 Hz personalized-fMRI and E-field modeling guided rTMS (3000 pulses/session) over the left DLPFC.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sham rTMS
Arm Type
Sham Comparator
Arm Description
Participants will be fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device with adjustable output amplitude and powered by a 9-V battery. We will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses or 1 Hz over mOFC total 900 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.
Arm Title
Active rTMS 10 Hz DLPFC
Arm Type
Active Comparator
Arm Description
A stimulation frequency of 10 Hz, pulse train duration (on time) of 5 seconds, inter-train interval (off time) of 10 seconds (15 second cycle time), E-field-modeling to determine TMS intensity and coil orientation, total of 60 trains, session time of 15 minutes, and 3000-total pulses per day, will be delivered over the left DLPFC.
Arm Title
Active rTMS 1 Hz mOFC
Arm Type
Active Comparator
Arm Description
A stimulation frequency of 1Hz, E-field-modeling to determine TMS intensity and coil orientation, session time of 15 minutes, and 900-total pulses per day, will be the same for all subjects (both active and sham). TMS will be delivered over the left mOFC.
Intervention Type
Device
Intervention Name(s)
Sham rTMS
Intervention Description
Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
Intervention Type
Device
Intervention Name(s)
Active rTMS 10 Hz DLPFC
Intervention Description
10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
Intervention Type
Device
Intervention Name(s)
Active rTMS 1 Hz mOFC
Intervention Description
1 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left medial orbitofrontal cortex (mOFC).
Primary Outcome Measure Information:
Title
Mean number of cigarettes smoked per day
Description
The primary objective is to compare 1 Hz-mOFC rTMS to 10 Hz-DLPFC rTMS. Cigarettes smoked per day will be the primary outcome measure.
Time Frame
3-week rTMS treatment
Title
Changes of brain connectivity
Description
Compared to sham rTMS, either active rTMS significantly increase the negative correlation between DLPFC and NAc, DLPFC and mOFC, while decrease the correlation coefficient between NAc and mOFC.
Time Frame
Pre and post 3-week treatment
Secondary Outcome Measure Information:
Title
The percentage of participants who have quit by their target quit date
Description
Quit smoke rate on the target quit the date will be measured during the phase.
Time Frame
4-week follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Be between the ages of 18 and 60 years old. Smoke 10 or more cigarettes per day and have a carbon monoxide (CO) level > 10 ppm indicative of recent smoking. Have not received substance abuse treatment within the previous 30 days. Meet the criteria for tobacco use disorder as determined by DSM-5. Be in stable mental and physical health. If female, test non-pregnant and use adequate birth control. Show no evidence of focal or diffuse brain lesions on MRI. Be willing to provide informed consent. Be able to comply with protocol requirements and likely to complete all study procedures. Be motivated to quit smoking (based on responses of "very likely," or "somewhat likely" in the motivation questionnaire). Exclusion Criteria: Current moderate to severe substance use of any psychoactive substances other than nicotine or caffeine, as defined by DSM-V criteria. Contraindications to MRI (e.g., presence of metal in the skull, orbital or intracranial cavity, or having claustrophobia). Contraindication to rTMS. History of autoimmune, endocrine, viral, or vascular disorders affecting the brain. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment. Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea. Lifetime history of major Axis I disorders such as: bipolar affective disorder (BPAD), schizophrenia, post-traumatic stress disorder (PTSD), dementia, suicidal ideation or major depression. Self-report of >21 standard alcohol drinks per week in any week in the 30 days prior to screening. Use of other forms of nicotine delivery, such as nicotine patches, electronic cigarettes, gum, nasal spray, inhalers, and nicotine lozenges. Use of other tobacco products, including cigars, cigarillos, chew, snuff, and pouches/snus. Previous treatment with TMS.
Facility Information:
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xingbao Li, M.D
Phone
843-792-5729
Email
lixi@musc.edu
First Name & Middle Initial & Last Name & Degree
Xingbao Li, M.D

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28898485
Citation
Li X, Sahlem GL, Badran BW, McTeague LM, Hanlon CA, Hartwell KJ, Henderson S, George MS. Transcranial magnetic stimulation of the dorsal lateral prefrontal cortex inhibits medial orbitofrontal activity in smokers. Am J Addict. 2017 Dec;26(8):788-794. doi: 10.1111/ajad.12621. Epub 2017 Sep 12.
Results Reference
background
PubMed Identifier
28319755
Citation
Li X, Du L, Sahlem GL, Badran BW, Henderson S, George MS. Repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex reduces resting-state insula activity and modulates functional connectivity of the orbitofrontal cortex in cigarette smokers. Drug Alcohol Depend. 2017 May 1;174:98-105. doi: 10.1016/j.drugalcdep.2017.02.002. Epub 2017 Feb 28.
Results Reference
background
PubMed Identifier
25038985
Citation
Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M, Zangen A. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. 2014 Nov 1;76(9):742-9. doi: 10.1016/j.biopsych.2014.05.020. Epub 2014 Jun 5.
Results Reference
background
PubMed Identifier
23485014
Citation
Li X, Hartwell KJ, Owens M, Lematty T, Borckardt JJ, Hanlon CA, Brady KT, George MS. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. Biol Psychiatry. 2013 Apr 15;73(8):714-20. doi: 10.1016/j.biopsych.2013.01.003. Epub 2013 Feb 26.
Results Reference
result
PubMed Identifier
32534252
Citation
Li X, Hartwell KJ, Henderson S, Badran BW, Brady KT, George MS. Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial. Brain Stimul. 2020 Sep-Oct;13(5):1271-1279. doi: 10.1016/j.brs.2020.06.007. Epub 2020 Jun 10.
Results Reference
result

Learn more about this trial

RTMS Targets Neural Circuits for Smoking Cessation

We'll reach out to this number within 24 hrs